Marygold Companies (AMEX:MGLD) reported $8.77 million in sales this quarter.
Avidity Biosciences Announces Topline Data From AOC 1001 Phase 1/2 MARINA Trial Demonstrating Functional Improvement, Disease Modification And Favorable Safety And Tolerability Profile In People Living With Myotonic Dystrophy Type 1
Topline data presented at AAN annual meeting showed AOC 1001 achieved directional improvements in multiple functional endpoint assessments - myotonia (vHOT), measures of strength (total QMT) and mobility (10mWRT, Timed